- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03258931
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
May 21, 2020 updated by: Arog Pharmaceuticals, Inc.
Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation.
About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B).
Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation.
Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
510
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: General Contact
- Phone Number: 214-593-0500
- Email: info@arogpharma.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope National Medical Center
-
Contact:
- Chatchada Karanes, MD
- Phone Number: 626-218-2405
- Email: CKaranes@coh.org
-
Los Angeles, California, United States, 90095
- Recruiting
- Ronald Reagan UCLA Medical Center
-
Contact:
- Caspian Oliai, MD
- Phone Number: 310-206-5756
- Email: COliai@mednet.ucla.edu
-
Sacramento, California, United States, 95817
- Recruiting
- US Davis Health
-
Contact:
- Brian Jonas, MD
- Phone Number: 800-282-3284
- Email: bajonas@ucdavis.edu
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale Cancer Center
-
Contact:
- Nikolai Podoltsev, MD
- Phone Number: 203-737-7059
- Email: nikolai.podoltsev@yale.edu
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Kendra Sweet, MD
- Phone Number: 813-745-6841
- Email: Kendra.Sweet@moffitt.org
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
Contact:
- Hongtao Liu, MD
- Phone Number: 773-834-0589
- Email: hliu2@medicine.bsd.uchicago.edu
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois at Chicago
-
Contact:
- John G Quigley, MD
- Phone Number: 312-413-1300
- Email: seanq@uic.edu
-
Chicago, Illinois, United States, 60612
- Recruiting
- Rush Medical Center
-
Contact:
- Melissa Larson, MD
- Phone Number: 312-942-5978
- Email: melissa_larson@rush.edu
-
-
Indiana
-
Indianapolis, Indiana, United States, 46206-5149
- Recruiting
- Indiana University
-
Contact:
- Heiko Konig, MD
- Phone Number: 317-274-3590
- Email: hkonig@iupui.edu
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa Hospitals and Clinics
-
Contact:
- Carlos Vigil-Gonzales, MD
- Phone Number: 319-356-1206
- Email: carlos-vigil@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas
-
Contact:
- Sunil Abhyankar, MD
- Phone Number: 913-588-9281
- Email: sabhyankar@kumc.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Amir Fathi, MD
- Phone Number: 617-724-1124
- Email: AFATHI@mgh.harvard.edu
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Beth Israel Deacnss Medical Center Oncology
-
Contact:
- Malgorzata McMasters, MD
- Phone Number: 617-667-9920
- Email: mmcmaste@bidmc.harvard.edu
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Insitute
-
Contact:
- Richard M Stone, MD
- Phone Number: 617-632-2214
- Email: Richard_Stone@dfci.harvard.edu
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health System
-
Contact:
- Yue Guo, MD
- Phone Number: 800-436-7936
- Email: YGUO1@hfhs.org
-
Detroit, Michigan, United States, 48201
- Recruiting
- Karmanos Cancer Institute
-
Contact:
- Jay Yang, MD
- Phone Number: 800-527-6266
- Email: yangj@karmanos.org
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Erica Warlick, MD
- Phone Number: 612-625-5467
- Email: ewarlick@umn.edu
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- John Theurer Cancer Center At Hackensack UMC
-
Contact:
- Jamie Koprivnikar, MD
- Phone Number: 551-996-5900
- Email: Jamie.Koprivnikar@hackensackmeridian.org
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Athena Kritharis, MD
- Phone Number: 732-235-4439
- Email: athena.kritharis@rutgers.edu
-
-
New York
-
Bronx, New York, United States, 10467
- Recruiting
- Montefiore Medical Center
-
Contact:
- Aditi Shastri, MD
- Phone Number: 718-920-4826
- Email: ASHASTRI@montefiore.org
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park
-
Contact:
- Eunice S Wang, MD
- Phone Number: 716-845-3544
- Email: eunice.wang@roswellpark.org
-
New York, New York, United States, 10016
- Recruiting
- New York University
-
Contact:
- Mohammad Abdul Hay, MD
- Phone Number: 646-501-4818
- Email: maher.abdulhay@nyulangone.org
-
New York, New York, United States, 10032
- Recruiting
- Columbia University
-
Contact:
- Joseph Jurcic, MD
- Phone Number: 646-317-5077
- Email: jgj2110@cumc.columbia.edu
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan-Kettering Cancer Center
-
Contact:
- Aaron Goldberg, MD
- Phone Number: 212-639-2126
- Email: goldbera@mskcc.org
-
New York, New York, United States, 10029-6574
- Recruiting
- Mount Sinai
-
Contact:
- John Mascarenhas, MD
- Phone Number: 212-241-3417
- Email: John.mascarenhas@mssm.edu
-
New York, New York, United States, 10065
- Recruiting
- Cornell University
-
Contact:
- Pinkal Desai, MD
- Phone Number: 646-962-2700
- Email: pid9006@med.cornell.edu
-
New York, New York, United States, 14642
- Recruiting
- University of Rochester Medical Center
-
Contact:
- Jane Liesveld, MD
- Phone Number: 585-275-5295
- Email: jane_liesveld@urmc.rochester.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- The UNC Lineberger Comprehensive Cancer Center
-
Contact:
- Joshua Zeidner, MD
- Phone Number: 919-966-4432
- Email: joshua_zeidner@med.unc.edu
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Baptist Health, Section on Hematology & Oncology
-
Contact:
- Rupali Roy Bhave, MD
- Phone Number: 336-713-0864
- Email: rbhave@wakehealth.edu
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health and Science University
-
Contact:
- Elie Traer, MD
- Phone Number: 503-418-9614
- Email: traere@ohsu.edu
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- University of Virginia Health System
-
Contact:
- Michael Keng, MD
- Phone Number: 319-356-1206
- Email: MK2PV@hscmail.mcc.virginia.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification
- Presence of FLT3-ITD and/or D835 mutation(s) in bone marrow or peripheral blood
- Age ≥ 18 years and ≤ 60 years
- Adequate hepatic function within 48 hours prior to induction chemotherapy
- Adequate renal functions within 48 hours prior to induction chemotherapy
- ECOG performance status within 48 hours prior to induction chemotherapy ≤ 3
- Eligible for intensive cytarabine/daunorubicin (7+3) chemotherapy specified
Exclusion Criteria:
- Acute promyelocytic leukemia (APL)
- Known clinically active central nervous system (CNS) leukemia
- Severe liver disease
- Active infections
- Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Known infection with human immunodeficiency virus (HIV)
- Prior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Crenolanib
Crenolanib following salvage chemotherapy
|
Crenolanib will be administered orally
Other Names:
100 mg/m² IV continuous infusion over 24 hours
90 mg/m2 IV
|
Active Comparator: Midostaurin
Midostaurin following salvage chemotherapy
|
100 mg/m² IV continuous infusion over 24 hours
90 mg/m2 IV
Midostaurin will be administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Event-free survival (EFS)
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of response
Time Frame: 5 years
|
5 years
|
Relapse free survival
Time Frame: 5 years
|
5 years
|
Overall Survival
Time Frame: 7 years
|
7 years
|
Composite complete remission rate
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 15, 2018
Primary Completion (Anticipated)
November 1, 2022
Study Completion (Anticipated)
November 1, 2024
Study Registration Dates
First Submitted
August 21, 2017
First Submitted That Met QC Criteria
August 21, 2017
First Posted (Actual)
August 23, 2017
Study Record Updates
Last Update Posted (Actual)
May 22, 2020
Last Update Submitted That Met QC Criteria
May 21, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protein Kinase Inhibitors
- Cytarabine
- Midostaurin
- Crenolanib
Other Study ID Numbers
- ARO-021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newly Diagnosed FLT3 Mutated AML
-
Arog Pharmaceuticals, Inc.CompletedNewly Diagnosed AML With FLT3 Activating MutationsUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnRelapsed/Refractory FLT3-mutated AML
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer CenterActive, not recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingNewly Diagnosed Acute Myeloid Leukemia (AML)China
-
The University of Hong KongUnknownAML | FLT3-ITD MutationHong Kong
-
Ain Shams UniversityUnknownNewly Diagnosed Pediatric ITPEgypt
-
German Cancer Research CenterCharite University, Berlin, Germany; Roche Pharma AG; Johannes Gutenberg University... and other collaboratorsRecruitingNewly Diagnosed H3-mutated GliomaGermany
-
Istituto Scientifico Romagnolo per lo Studio e...UnknownAML | FLT3-ITD Mutation | FLT3-TKD MutationItaly
-
Freenome Holdings Inc.RecruitingNewly-diagnosed Cancers | Non-cancer ControlsUnited States
-
French Innovative Leukemia OrganisationAcute Leukemia French AssociationRecruitingAML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITDFrance
Clinical Trials on Crenolanib
-
Arog Pharmaceuticals, Inc.Terminated
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesUnited States
-
Arog Pharmaceuticals, Inc.CompletedRecurrent/Refractory GlioblastomaUnited States
-
Arog Pharmaceuticals, Inc.AvailableFLT3-ITD Mutation | FLT3/TKD Mutation | PDGFR-Alpha D842V | PDGFRA Gene AmplificationItaly
-
Arog Pharmaceuticals, Inc.Centre Leon Berard; Fox Chase Cancer CenterUnknownGIST With D842V Mutated PDGFRA GeneUnited States, France, Spain, Italy, Germany, Norway, Poland
-
Arog Pharmaceuticals, Inc.CompletedD842-related Mutant GISTUnited States
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid LeukemiaUnited States
-
Arog Pharmaceuticals, Inc.CompletedPhase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsRelapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States
-
St. Jude Children's Research HospitalArog Pharmaceuticals, Inc.; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine Glioma | Progressive or Refractory High-Grade GliomaUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnRelapsed/Refractory FLT3-mutated AML